Loading...

iCAD, Inc.

ICADNASDAQ
Healthcare
Medical - Devices
$3.87
$0.14(3.75%)

iCAD, Inc. (ICAD) Financial Performance & Income Statement Overview

Analyze iCAD, Inc. (ICAD) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
13.22%
13.22%
Operating Income Growth
18.48%
18.48%
Net Income Growth
-15.87%
15.87%
Operating Cash Flow Growth
20.53%
20.53%
Operating Margin
-30.50%
30.50%
Gross Margin
85.57%
85.57%
Net Profit Margin
-26.77%
26.77%
ROE
-17.45%
17.45%
ROIC
-18.74%
18.74%

iCAD, Inc. (ICAD) Income Statement & Financial Overview

Review iCAD, Inc. ICAD income statement with detailed quarterly and annual figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$4.87M$5.41M$4.22M$5.03M
Cost of Revenue$685000.00$738000.00$583000.00$812000.00
Gross Profit$4.19M$4.67M$3.63M$4.22M
Gross Profit Ratio$0.86$0.86$0.86$0.84
R&D Expenses$1.48M$1.41M$1.93M$1.76M
SG&A Expenses$3.79M$4.06M$3.67M$4.34M
Operating Expenses$5.26M$5.54M$5.65M$6.10M
Total Costs & Expenses$5.95M$6.15M$6.23M$6.98M
Interest Income$172000.00$192000.00$210000.00$206000.00
Interest Expense$0.00$12000.00$0.00$0.00
Depreciation & Amortization$114000.00$174000.00$113000.00$177000.00
EBITDA-$1.01M-$589000.00-$1.68M-$1.55M
EBITDA Ratio-$0.21-$0.11-$0.40-$0.31
Operating Income-$1.13M-$865000.00-$2.02M-$1.95M
Operating Income Ratio-$0.23-$0.16-$0.48-$0.39
Other Income/Expenses (Net)$296000.00$90000.00$220000.00$217000.00
Income Before Tax-$833000.00-$775000.00-$1.79M-$1.73M
Income Before Tax Ratio-$0.17-$0.14-$0.43-$0.34
Income Tax Expense$0.00$79000.00$6000.00$8000.00
Net Income-$833000.00-$854000.00-$1.80M-$1.74M
Net Income Ratio-$0.17-$0.16-$0.43-$0.35
EPS-$0.03-$0.03-$0.07-$0.07
Diluted EPS-$0.03-$0.03-$0.07-$0.07
Weighted Avg Shares Outstanding$26.71M$26.35M$26.35M$26.35M
Weighted Avg Shares Outstanding (Diluted)$26.71M$26.35M$26.35M$26.35M

Over the past four quarters, iCAD, Inc. demonstrated steady revenue growth, increasing from $5.03M in Q2 2024 to $4.87M in Q1 2025. Operating income reached -$1.13M in Q1 2025, maintaining a consistent -23% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$1.01M, reflecting operational efficiency. Net income rose to -$833000.00, with EPS at -$0.03. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;